Compare Bristol-Myers Squibb Co (BMY) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.21 (market cap $78.85B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MDLZ | |
|---|---|---|
Market Cap | $129.94B | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $64.99 |
52-Week Low | $42.60 | $51.51 |
Enterprise Value | $163.92B | $99.19B |
Dividend Yield | 3.96% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
MDLZ trades at $61.99, up 0.75% today, with a bullish technical signal from moving averages and support at $61. The company reported Q2 2026 EPS of $0.73, beating estimates, and raised its organic sales outlook. Revenue grew to $38.54B in 2025, though net income margin declined to 6.36%. Analyst consensus is strongly bullish with a $70.50 price target.
Outlook is positive due to earnings beats and emerging market growth, but risks include margin pressure and high P/E of 37.75. Institutional activity is mixed, with some firms increasing stakes while others reduced holdings. The stock offers upside to target but faces execution risks in a competitive consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
